ZA941729B - Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5). - Google Patents

Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5).

Info

Publication number
ZA941729B
ZA941729B ZA941729A ZA941729A ZA941729B ZA 941729 B ZA941729 B ZA 941729B ZA 941729 A ZA941729 A ZA 941729A ZA 941729 A ZA941729 A ZA 941729A ZA 941729 B ZA941729 B ZA 941729B
Authority
ZA
South Africa
Prior art keywords
fgf
treatment
growth factor
fibroblast growth
motor neuron
Prior art date
Application number
ZA941729A
Inventor
Richard A Hughes
Michael Sendtner
Dan Lindholm
Hans F E Thoenen
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of ZA941729B publication Critical patent/ZA941729B/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA941729A 1993-03-12 1994-03-11 Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5). ZA941729B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3061193A 1993-03-12 1993-03-12

Publications (1)

Publication Number Publication Date
ZA941729B true ZA941729B (en) 1994-10-13

Family

ID=21855051

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA941729A ZA941729B (en) 1993-03-12 1994-03-11 Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5).

Country Status (4)

Country Link
AU (1) AU6284194A (en)
IL (1) IL108950A0 (en)
WO (1) WO1994020125A1 (en)
ZA (1) ZA941729B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111786A0 (en) * 1993-12-01 1995-01-24 Max Planck Gesellschaft Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
ATE226444T1 (en) * 1998-03-12 2002-11-15 Genentech Inc USE OF FGF-5 POLYPETIDES TO PREVENT RETINAL NEURON DEATH AND TREAT OCCULAR DISEASES
WO2001000662A2 (en) * 1999-06-29 2001-01-04 Eli Lilly And Company The use of human fgh-8 polypeptides as neurotrophic agents
AU774958B2 (en) * 1999-10-02 2004-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Fibroblast growth factor-5 (FGF-5) is a tumor associated T-cell antigen
CN100531796C (en) * 2002-01-31 2009-08-26 马普科技促进协会 FGFR agonists
JP4731487B2 (en) * 2004-08-24 2011-07-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 Method for discriminating types of spinal nerve cells targeting the Corl1 gene

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor
WO1994003199A1 (en) * 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells

Also Published As

Publication number Publication date
WO1994020125A1 (en) 1994-09-15
IL108950A0 (en) 1994-06-24
AU6284194A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
AU7567394A (en) Treatment chamber catheter
AU4997093A (en) Treatment of alzheimer's disease and modulation of immune system with delta5-androstenes
AU4350296A (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
EP0690871A4 (en) Growth differentiation factor-5
ZA931174B (en) Treatment of disease employing hyaluronic acid and nsaids.
AU7540591A (en) Sludge treatment process
EP0594410A3 (en) Treatment of rubber articles.
AU1173195A (en) Treatment of immunoregulatory disorders
ZA941729B (en) Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5).
AU1278295A (en) Wastewater treatment
AU1480497A (en) Cancer treatment
AU2653095A (en) Fibroblast growth factor-14
AU2653195A (en) Fibroblast growth factor 11
AU5340594A (en) Skin treatment
AU5518694A (en) Treatment of a group of related disorders
AU7877894A (en) Treatment of hiv infection with humic acid
ZA931063B (en) Treatment of glaucoma.
AU2697995A (en) Fibroblast growth factor 13
AU8185491A (en) Treatment of disease
AU2593692A (en) Biological wastewater treatment process
AU2754997A (en) The treatment of plant diseases
AU3641993A (en) Treatment chamber
AU4334297A (en) Antiviral treatment
AU5556094A (en) Nucleotide sequence for treating cancer and infection
ZA949535B (en) Methods of promoting the survival and differentiation of subclasses of cholinergic and serotonergic neurons using fibroblast growth factor-5.